Van Tran Tran Thi, Chang Hsun-Shuo, Wu Ho-Cheng, Lu Chung-Kuang, Huang Hui-Chi, Korinek Michal, Hsiao Hui-Hua, Yen Chia-Hung
Graduate Institute of Natural Products, Kaohsiung Medical University, Kaohsiung, Taiwan.
Drug Development and Value Creation Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan.
Front Pharmacol. 2024 Jul 25;15:1403424. doi: 10.3389/fphar.2024.1403424. eCollection 2024.
Bortezomib (BTZ), a primary treatment for MM, but its effectiveness can be reduced by interactions with vicinal diol moieties (VDMs) in polyphenols. Despite this, it's debated whether BTZ therapy necessitates avoiding polyphenol-rich products, given the low bioavailability of polyphenols. Additionally, it remains unclear whether the structure of polyphenols contributes to their BTZ antagonism. Therefore, our study aims to unravel the structure-activity relationship of dietary polyphenols and their BTZ antagonism at daily diet-achievable physiological concentrations. We assessed the antagonistic effects of 25 polyphenols against BTZ using cell viability assays in RPMI 8226 cells. ChemGPS-NP helped analyze the structural similarity. Additionally, long-term cytotoxicity assays evaluated these effects at physiologically relevant concentrations. By cell viability assays, we found a positive correlation between the number of VDMs in gallotannins and their BTZ antagonism. Moreover, the origin and configuration of VDMs, rather than the total VDM concentration, play a pivotal role in the combined antagonistic effects against BTZ in gallotannins. Additionally, ChemGPS-NP analysis indicated that the aromaticity and C-3 hydroxyl group in flavonoids' C-rings enhance their BTZ antagonism. Finally, long-term cytotoxicity assays reveal that gallic acid (GA), epigallocatechin (EGC), and epigallocatechin gallate (EGCG), at their physiological concentrations-attainable through tea consumption-significantly and synergistically antagonize BTZ. Due to the potential for these polyphenols to reduce the effectiveness of BTZ, it is advisable for MM patients undergoing BTZ treatment to reduce their consumption of foods high in VDM-containing polyphenols.
硼替佐米(BTZ)是多发性骨髓瘤的主要治疗药物,但其有效性会因与多酚中的邻二醇部分(VDMs)相互作用而降低。尽管如此,鉴于多酚的生物利用度较低,对于BTZ治疗是否需要避免富含多酚的产品仍存在争议。此外,多酚的结构是否导致其对BTZ的拮抗作用仍不清楚。因此,我们的研究旨在揭示日常饮食可达到的生理浓度下膳食多酚的构效关系及其对BTZ的拮抗作用。我们在RPMI 8226细胞中使用细胞活力测定法评估了25种多酚对BTZ的拮抗作用。ChemGPS-NP有助于分析结构相似性。此外,长期细胞毒性测定法在生理相关浓度下评估了这些作用。通过细胞活力测定,我们发现没食子单宁中VDMs的数量与其对BTZ的拮抗作用呈正相关。此外,VDMs的来源和构型而非总VDM浓度在没食子单宁对BTZ的联合拮抗作用中起关键作用。此外,ChemGPS-NP分析表明黄酮类化合物C环中的芳香性和C-3羟基增强了它们对BTZ的拮抗作用。最后,长期细胞毒性测定表明,通过饮茶可达到的生理浓度下的没食子酸(GA)、表没食子儿茶素(EGC)和表没食子儿茶素没食子酸酯(EGCG)显著且协同地拮抗BTZ。由于这些多酚有可能降低BTZ的有效性,建议接受BTZ治疗的多发性骨髓瘤患者减少食用富含含VDM多酚的食物。